International Journal of Hematology

, Volume 91, Issue 2, pp 284–292 | Cite as

Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study

  • Hisashi Sakamaki
  • Shuichi Miyawaki
  • Shigeki Ohtake
  • Nobuhiko Emi
  • Fumiharu Yagasaki
  • Kinuko Mitani
  • Shin Matsuda
  • Yuji Kishimoto
  • Yasushi Miyazaki
  • Norio Asou
  • Masatomo Takahashi
  • Yoshiaki Ogawa
  • Sumihisa Honda
  • Ryuzo Ohno
Original Article


We prospectively compared allogeneic hematopoietic stem cell transplantation (allo-HSCT) with chemotherapy as a post-remission therapy in a multicenter trial (JALSG AML97) of adult patients with intermediate or poor risk acute myeloid leukemia (AML). Of 503 patients aged 15–50 years old registered between December 1997 and July 2001, 392 achieved complete remission (CR). CR patients classified in the intermediate or poor risk group using a new scoring system were tissue typed. Seventy-three with and 92 without an HLA-identical sibling were assigned to the donor and no-donor groups. Of 73 patients in the donor group, 38 (52%) received allo-HSCT during CR1 and 17 (23%) after relapse. Intention-to-treat analysis revealed that the relapse incidence was reduced in the donor group (52 vs. 77%; p = 0.008), and the disease-free survival (DFS) improved (39 vs. 19%; p = 0.016), but overall survival (OS) was not significantly different (46 vs. 29%; p = 0.088). The OS benefit was seen in the patients aged 36–50 years old (49 vs. 24%; p = 0.031), suggesting an advantage of allo-HSCT among older patients with leukemia that is more resistant to chemotherapy than that among younger patients.


AML Allogeneic hematopoietic stem cell transplantation Post-remission chemotherapy 


  1. 1.
    Ohno R, Kobayashi T, Tanimoto M, et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer. 1993;71(12):3888–95.CrossRefPubMedGoogle Scholar
  2. 2.
    Kobayashi T, Miyawaki S, Tanimoto M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol. 1996;14(1):204–13.PubMedGoogle Scholar
  3. 3.
    Miyawaki S, Tanimoto M, Kobayashi T, et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol. 1999;70(2):97–104.PubMedGoogle Scholar
  4. 4.
    Buchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003;21(24):4496–504.CrossRefPubMedGoogle Scholar
  5. 5.
    Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005;105(9):3420–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896–903.CrossRefPubMedGoogle Scholar
  7. 7.
    Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339(23):1649–56.CrossRefPubMedGoogle Scholar
  8. 8.
    Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1997;90(8):2978–86.PubMedGoogle Scholar
  9. 9.
    Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58(18):4173–9.PubMedGoogle Scholar
  10. 10.
    Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118(2):385–400.CrossRefPubMedGoogle Scholar
  11. 11.
    Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767–75.PubMedGoogle Scholar
  12. 12.
    Schlenk RF, Benner A, Hartmann F, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17(8):1521–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102(4):1232–40.CrossRefPubMedGoogle Scholar
  14. 14.
    Kuriyama K, Tomonaga M, Kobayashi T, et al. Trial to extract prognostic factors prior to the start of induction chemotherapy for adult AML. Berlin: Springer; 1998. p. 901–5.Google Scholar
  15. 15.
    Miyawaki S, Sakamaki H, Ohtake S, et al. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Cancer. 2005;104(12):2726–34.CrossRefPubMedGoogle Scholar
  16. 16.
    Kaplan E, Meier P. Non parametric estimation from imcomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  17. 17.
    Keating S, de Witte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Br J Haematol. 1998;102(5):1344–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Jourdan E, Boiron JM, Dastugue N, et al. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol. 2005;23(30):7676–84.CrossRefPubMedGoogle Scholar
  19. 19.
    Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658–66.CrossRefPubMedGoogle Scholar
  20. 20.
    Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005;103(8):1652–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant. 1991;7(Suppl 3):9–12.PubMedGoogle Scholar
  22. 22.
    Frassoni F, Labopin M, Gluckman E, et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time–a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 1996;17(1):13–8.PubMedGoogle Scholar
  23. 23.
    Bacigalupo A, Sormani MP, Lamparelli T, et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2004;89(10):1238–47.PubMedGoogle Scholar
  24. 24.
    Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–18.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  • Hisashi Sakamaki
    • 1
  • Shuichi Miyawaki
    • 2
  • Shigeki Ohtake
    • 3
  • Nobuhiko Emi
    • 4
  • Fumiharu Yagasaki
    • 5
  • Kinuko Mitani
    • 6
  • Shin Matsuda
    • 7
  • Yuji Kishimoto
    • 8
  • Yasushi Miyazaki
    • 9
  • Norio Asou
    • 10
  • Masatomo Takahashi
    • 11
  • Yoshiaki Ogawa
    • 12
  • Sumihisa Honda
    • 13
  • Ryuzo Ohno
    • 14
  1. 1.Division of HematologyTokyo Metropolitan Komagome HospitalTokyoJapan
  2. 2.Division of HematologyTokyo Metropolitan Ohtsuka HospitalTokyoJapan
  3. 3.Department of Clinical Laboratory ScienceKanazawa University Graduate School of Medical ScienceKanazawaJapan
  4. 4.Department of HematologyFujita Health UniversityAichiJapan
  5. 5.Department of Internal Medicine (Hematology)Saitama Medical SchoolSaitamaJapan
  6. 6.Department of HematologyDokkyo University School of MedicineTochigiJapan
  7. 7.Center for Hematopoietic DisordersOhtanisinouchi HospitalKohriyamaJapan
  8. 8.The First Department of Internal MedicineKansai Medical UniversityOsakaJapan
  9. 9.The Department of Hematology, Atomic Bomb Disease InstituteNagasaki University School of MedicineNagasakiJapan
  10. 10.Department of HematologyKumamoto University School of MedicineKumamotoJapan
  11. 11.Division of Hematology and Oncology, Department of Internal MedicineSt. Marianna University School of MedicineKawasakiJapan
  12. 12.Department of Hematology and OncologyTokai University School of MedicineKanagawaJapan
  13. 13.Department of Radiation Epidemiology, Atomic Bomb Disease InstituteNagasaki University School of MedicineNagasakiJapan
  14. 14.Aichi Cancer CenterAichiJapan

Personalised recommendations